Marché européen de la distribution de médicaments – Tendances et prévisions du secteur jusqu’en 2030

Analyse et taille du marché de la distribution de médicaments en Europe

L'augmentation des maladies chroniques et infectieuses est l'un des principaux moteurs du marché européen de l'administration de médicaments. Les maladies infectieuses ont connu une épidémie soudaine et se développent à un rythme jamais vu au cours des 5 à 6 dernières décennies. La croissance du marché de l'administration de médicaments s'est accélérée avec l'acceptation croissante des médicaments auto-administrés et la sensibilisation au diagnostic et au traitement dans les pays développés et en développement. En outre, l'incidence croissante des maladies cardiovasculaires est devenue une source de préoccupation majeure en matière de santé publique.

 Data Bridge Market Research analyse le taux de croissance du marché de l'administration de médicaments au cours de la période de prévision 2023-2030. Le TCAC attendu du marché de l'administration de médicaments a tendance à être d'environ 7,7 % au cours de la période de prévision mentionnée. Le marché est évalué à 391,2 millions USD en 2022 et devrait atteindre 708,15 millions USD d'ici 2030. En plus des informations sur le marché telles que la valeur marchande, le taux de croissance, les segments de marché, la couverture géographique, les acteurs du marché et le scénario du marché, le rapport de marché élaboré par l'équipe de Data Bridge Market Research comprend également une analyse approfondie des experts, une épidémiologie des patients, une analyse du pipeline, une analyse des prix et un cadre réglementaire.

Portée et segmentation du marché de l'administration de médicaments en Europe

Définition du marché

Drug delivery is the process of introducing a therapeutic effect in the body of human by administering a drug at a specific targeted site. The safety and efficacy of drug can be improved by controlling the rate, time and release of drug in the body. There can be several ways of delivering drugs such as oral, pulmonary, nasal, injectable, and others. The drug delivery systems are advanced by studying and developing the properties of nanoparticles, which have made the drug delivery process more efficient and time-saving.

Europe Drug Delivery Market Dynamics

Drivers

• Increasing Product Developments

Various product developments are started by numerous companies worlwide which are also increasing the growth of market. For instance, Janssen Pharmaceutical Companies of Johnson & Johnson Services, Inc. in February 2020 told about submitting a supplemental Biologics License Application (sBLA) to the U.S. FDA of DARZALEX combined with Kyprolis and dexamethasone which is used for the treatment of relapsed or refractory multiple myeloma. This as a result, increases the demand for the market.

• Rising Cases of Cardiovascular Diseases

The growing occurrence of cardiovascular diseases (CVDs) has become a major public health concern. CVDs are primarily responsible for approximately 46% of the total mortality rate in the country. Injectable drug delivery technology has developed as a source of relief for the elderly and CVD patients since they help provide a better quality of life. This factor is boosting the growth of the KSA injectable drug delivery market during the forecast period 2023-2029. Thus, this factor increases the market growth.

Opportunities

• Increasing Preference Towards Feasible Routes of Administration

One of the developing trends in the topical drug delivery market is the delivery of biologics through the transdermal route. The wide use of transdermal delivery of big molecules provides significant patient benefits such as painless medication delivery and cost-effective treatment. This factor is expected to increase the growth of the market. Additionally, the preference towards administration of drugs through the skin to control or extend drug delivery and the use of this process as a substitute to the oral route are also projected to boost market growth.

• Increasing Demand For Rising Cancer Cases

According to Cancer Research UK 2018, the population suffering from cancer is projected to surge in the future. As per the report, if the current trends in the occurrence of major cancers and population growth are persistent, it is expected there will be 27.5 million new cancer cases worldwide every year by 2040, more than 17 million in 2018. Furthermore, in European regions such as the UK there is also an increase in incident cases of cancer, as per Cancer Research UK's 2019 report. Thus, this factor increases the market growth.

Restraints/Challenges

• Increased Expenditure of Treatment

The high expenditure related with drug delivery and the huge cost required to conduct the assays hinder the market growth. The increased cost associated with the manufacturing, supply and drug delivery is often not possible for the developing and underdeveloped countries, cause the under treatment of numerous patients. This impedes the market growth.

This drug delivery market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the drug delivery market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In 2020, Bayer AG completed the submission of application for the U.S. approval of nifurtimox, which is a drug for treating pediatric patients with Chagas disease. This will fix the condition of children suffering from this disease and also benefit the company as it is a novel formulation for children and revenue generation will be increased for the organization.
• In 2019, F. Hoffmann-La Roche Ltd completed the acquisition of Spark Therapeutics, Inc. Spark is an organization that is dedicated to investigational gene therapy. This will open several opportunities for Roche and also will lead to more revenues.

Europe Drug Delivery Market Scope

The drug delivery market is segmented on the basis of product type, end user, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type  

• Oral Drug Delivery
• Pulmonary Drug Delivery
• Injectable Drug Delivery
• Opthalmic Drug Delivery
• Nasal Drug Delivery
• Topical Drug Delivery
• Implantable Drug Delivery
• Transmucosal Drug Delivery

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Drug Delivery Market Regional Analysis/Insights

The drug delivery market is analyzed and market size insights and trends are provided by product type, end user, and distribution channel as referenced above.

The major countries covered in the drug delivery market report are Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe.

L'Europe est en tête du marché en raison de l'augmentation du taux d'adoption de nombreuses nouvelles avancées technologiques dans l'administration de médicaments. En outre, l'augmentation de la population âgée et de l'augmentation du revenu disponible des habitants de la région accroît la croissance du marché.

La section par pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements de réglementation sur le marché national qui ont un impact sur les tendances actuelles et futures du marché. En outre, la présence et la disponibilité des marques européennes et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des tarifs nationaux et des routes commerciales sont pris en compte tout en fournissant une analyse prévisionnelle des données par pays.   

Analyse du paysage concurrentiel et des parts de marché du secteur de la distribution de médicaments en Europe

Le paysage concurrentiel du marché de l'administration de médicaments fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence en Europe, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit, la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liée au marché de l'administration de médicaments

Les principaux acteurs opérant sur le marché de l’administration de médicaments comprennent :

• Némera (France)
• F. Hoffmann-La Roche SA (Suisse)
• Mylan NV (États-Unis)
• Teva Pharmaceutical Industries Ltd. (Israël)
• Sanofi (France)
• Pfizer Inc. (États-Unis)
• GSK plc (Royaume-Uni)
• Novartis SA (Suisse)
• AstraZeneca (Royaume-Uni)
• Johnson & Johnson Private Limited (États-Unis)
• Merck & Co., Inc. (États-Unis)
• 3M (États-Unis)
• Bayer AG (Allemagne)
• Takeda Pharmaceutical Company Limited (Japon)

SKU-2287